101 related articles for article (PubMed ID: 27286708)
1. Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model.
Hashimoto Y; Tada M; Iida M; Nagase S; Hata T; Watari A; Okada Y; Doi T; Fukasawa M; Yagi K; Kondoh M
Biochem Biophys Res Commun; 2016 Aug; 477(1):91-95. PubMed ID: 27286708
[TBL] [Abstract][Full Text] [Related]
2. Safety evaluation of a human chimeric monoclonal antibody that recognizes the extracellular loop domain of claudin-2.
Hashimoto Y; Hata T; Tada M; Iida M; Watari A; Okada Y; Doi T; Kuniyasu H; Yagi K; Kondoh M
Eur J Pharm Sci; 2018 May; 117():161-167. PubMed ID: 29448044
[TBL] [Abstract][Full Text] [Related]
3. Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy.
Li X; Iida M; Tada M; Watari A; Kawahigashi Y; Kimura Y; Yamashita T; Ishii-Watabe A; Uno T; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):206-13. PubMed ID: 25118216
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody.
Hashimoto Y; Kawahigashi Y; Hata T; Li X; Watari A; Tada M; Ishii-Watabe A; Okada Y; Doi T; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
Pharmacol Res Perspect; 2016 Oct; 4(5):e00266. PubMed ID: 27713828
[TBL] [Abstract][Full Text] [Related]
5. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.
Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391
[TBL] [Abstract][Full Text] [Related]
6. Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.
Hashimoto Y; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
Ann N Y Acad Sci; 2017 Jun; 1397(1):5-16. PubMed ID: 28415141
[TBL] [Abstract][Full Text] [Related]
7. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.
Paciello R; Urbanowicz RA; Riccio G; Sasso E; McClure CP; Zambrano N; Ball JK; Cortese R; Nicosia A; De Lorenzo C
J Gen Virol; 2016 Jan; 97(1):82-94. PubMed ID: 26519290
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
[TBL] [Abstract][Full Text] [Related]
9. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
[TBL] [Abstract][Full Text] [Related]
10. Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting.
Yang H; Park H; Lee YJ; Choi JY; Kim T; Rajasekaran N; Lee S; Song K; Hong S; Choi JS; Shim H; Kim YD; Hwang S; Choi YL; Shin YK
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31905631
[TBL] [Abstract][Full Text] [Related]
11. Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection.
Shimizu Y; Yoneda K; Shirasago Y; Suzuki T; Tada M; Ishii-Watabe A; Sugiyama K; Suzuki T; Wakita T; Yagi K; Kondoh M; Fukasawa M
Biochem Biophys Res Commun; 2019 Jun; 514(3):785-790. PubMed ID: 31079928
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
13. Generation and evaluation of a chimeric antibody against coxsackievirus and adenovirus receptor for cancer therapy.
Sakamoto S; Inoue H; Kaneko MK; Ogasawara S; Kajikawa M; Urano S; Ohba SI; Kato Y; Kawada M
Cancer Sci; 2019 Nov; 110(11):3595-3602. PubMed ID: 31512325
[TBL] [Abstract][Full Text] [Related]
14. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.
Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q
FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558
[TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.
Yang Y; Guo Q; Xia M; Li Y; Peng X; Liu T; Tong X; Xu J; Guo H; Qian W; Hou S; Dai J; Wang H; Liu R; Guo Y
MAbs; 2015; 7(2):440-50. PubMed ID: 25679409
[TBL] [Abstract][Full Text] [Related]
16. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
[TBL] [Abstract][Full Text] [Related]
18. Claudin-1 Binder Enhances Epidermal Permeability in a Human Keratinocyte Model.
Nakajima M; Nagase S; Iida M; Takeda S; Yamashita M; Watari A; Shirasago Y; Fukasawa M; Takeda H; Sawasaki T; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2015 Sep; 354(3):440-7. PubMed ID: 26139628
[TBL] [Abstract][Full Text] [Related]
19. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
20. Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer.
Kuwada M; Chihara Y; Luo Y; Li X; Nishiguchi Y; Fujiwara R; Sasaki T; Fujii K; Ohmori H; Fujimoto K; Kondoh M; Kuniyasu H
Cancer Lett; 2015 Dec; 369(1):212-21. PubMed ID: 26342407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
